2023
DOI: 10.1101/2023.05.30.542695
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Non-invasive vagus nerve stimulation decreases vagally mediated heart rate variability

Kristin Kaduk,
Alessandro Petrella,
Sophie J. Müller
et al.

Abstract: The vagus nerve plays a critical role in balancing the body's physiological functions, including the cardiovascular system. Measures of heart rate (HR) and its variability (HRV) may provide non-invasive proxies of vagal activity in humans, but transcutaneous auricular vagus nerve stimulation (taVNS) has produced mixed effects so far — limited by a lack of studies stimulating the right branch. Here, we used a randomized cross-over design to study the effects of taVNS on HR and HRV. To estimate how the side of t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 83 publications
0
1
0
Order By: Relevance
“…BI is a clinical assessment tool used to measure an individual's ability to independently perform activities of daily living (ADLs). EMG will be recorded automatically by a computer software along with each treatment session, and the ECG features, including heart rate variability (HRV) and heart rate (HR) will be recorded before and after each taVNS treatment session as biomarkers reflecting the activation of vagal tone (33,34). Primary and secondary outcome measures, except for EMG and ECG, will be assessed the day before or at the latest the day after the first session and again after the 14th session.…”
Section: Outcome Measuresmentioning
confidence: 99%
“…BI is a clinical assessment tool used to measure an individual's ability to independently perform activities of daily living (ADLs). EMG will be recorded automatically by a computer software along with each treatment session, and the ECG features, including heart rate variability (HRV) and heart rate (HR) will be recorded before and after each taVNS treatment session as biomarkers reflecting the activation of vagal tone (33,34). Primary and secondary outcome measures, except for EMG and ECG, will be assessed the day before or at the latest the day after the first session and again after the 14th session.…”
Section: Outcome Measuresmentioning
confidence: 99%